drugset / Trial / NCT06982131

A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants

NCT06982131

Phase 1 Recruiting 40 enrolled Hoffmann-La Roche
RandomizedCrossoverDouble-blindBasic science

Summary

This is a randomized, investigator-and-participant-blind, placebo-controlled, fixed sequence, cross-over, Phase 1 study to investigate the safety, tolerability, and pharmacokinetics of multiple doses of orally administered RO7795081 and the effect of a steady-state dose of orally administered RO7795081 on the pharmacokinetics of pitavastatin and rosuvastatin in otherwise healthy, overweight or obese adult participants.

Timeline

Start
2025-06-04
Primary completion
2026-12-04
Completion
2026-12-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Pitavastatin Small molecule 1 mg
Subject RO7795081 Unknown Oral
Subject Rosuvastatin Small molecule 10 mg

Indications